KEDI Global Obesity Care Industry Top 2+ Index

Abbott's Q2 2026 earnings release is scheduled for July 16, 2026. Analysts forecast EPS of $1.28. Medium importance estimated as earnings typically drive >5% price movement expected.

Quarterly cash dividend of $1.25 per share has an ex-dividend date of June 12, 2026. The dividend is scheduled to be paid on June 26, 2026.

New Phase 3 data for the pipeline drug CagriSema to be presented at the American Diabetes Association (ADA) Scientific Sessions on June 7, 2026, with a low price impact scheduled.

Lululemon Athletica is scheduled to release its financial results for the first quarter of fiscal 2026 on June 4, 2026, after the market closes. High importance is estimated as earnings releases typically result in significant price volatility. scheduled

RBC Capital analysts forecast a price target of $43.00 for Life Time Group Holdings on June 2, 2026; target increases typically suggest a low positive impact, forecasted.

Positive results from the EMERALD-3 Phase III trial were presented at the ASCO 2026 meeting on 2026-06-01, showing that Imfinzi and Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in patients with unresectable liver cancer; high market impact (>=10%) expected due to significant clinical efficacy.

The European Commission granted marketing authorization for IMDYLLTRA® (tarlatamab) on 2026-06-01 for the treatment of ES-SCLC; expected to have a medium market impact of approximately 5% due to expanded market access.

New data for Cosentyx, ianalumab, and Scemblix to be presented at the EULAR and ASCO 2026 congresses on 2026-06-01, highlighting positive results in immunology and oncology scheduled. Medium importance is estimated as clinical data for key drugs typically drives a 5% market reaction scheduled.

Announced positive Phase 3 results for cancer drug Retevmo in early-stage RET fusion-positive non-small cell lung cancer, showing an 83% reduction in the risk of disease recurrence or death; high impact due to breakthrough clinical data expected

The US FDA approved Imfinzi in combination with BCG therapy for the treatment of adult patients with a specific type of high-risk, non-muscle-invasive bladder cancer on 2026-05-29; medium market impact (>=5%) expected due to indication expansion.

The CARES Phase III clinical program for anselamimab did not meet its primary endpoint on 2026-05-29, but a prespecified subgroup analysis showed a clinically meaningful benefit for patients with kappa light chain amyloidosis; low market impact (>=1%) expected due to mixed clinical results.

The FDA granted Breakthrough Therapy Designation for the investigational KRAS G12C inhibitor calderasib (MK-1084) on May 29, 2026.

CVS Caremark announced it will add Lilly's obesity drugs Foundayo and Zepbound to its preferred formularies, significantly expanding patient access; high impact due to increased market share expected

The US FDA extended the decision date for the SERENA-6 regulatory filing of camizestrant to 2026-05-28 to enable the review of additional data; low market impact (>=1%) expected due to regulatory delay.

CEO Lauren Hobart sold 20,083 shares for approximately $4.58 million following an option exercise. This was part of broader insider selling totaling $42.5 million over the prior three months with no insider purchases reported.